Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis
Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis have?
Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis has 11 citations in the OpenAlex counts ScholarIQ stores.
When was Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis published?
Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis has 2023 year in the ScholarIQ index.
What is the open-access status of Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis?
Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis has gold oa status in the ScholarIQ index.
What is the DOI of Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis?
The DOI for Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis is on the source record.
What is the PMID of Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis?
The PMID for Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis is on the source record.
What is the OpenAlex record for Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis?
The OpenAlex for Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis is on the source record.